Hemispherx Biopharma Inc (HEB)

0.48
0.01 1.90
AMEX : Health Care
Prev Close 0.49
Open 0.48
Day Low/High 0.47 / 0.48
52 Wk Low/High 0.06 / 0.21
Volume 41.55K
Avg Volume 242.10K
Exchange AMEX
Shares Outstanding 26.59M
Market Cap 13.03M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Hemispherx Biopharma Announces Financial Results For The Three Months Ended March 31, 2017

The company has generated revenues from the lots of newly manufactured Ampligen

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

Hemispherx Biopharma Announces Financial Results In Its Quarterly Report For The Nine Months Ended September 30, 2016

Hemispherx Biopharma Announces Financial Results In Its Quarterly Report For The Nine Months Ended September 30, 2016

Conference Call Scheduled for Tuesday, November 15, 2016 at 11:00 AM EST

Hemispherx Biopharma To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

Hemispherx Biopharma To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

Recent Articles on Hemispherx Biopharma by BioWorld and Pink Sheet Posted to Corporate Website

Hemispherx Biopharma Enters Into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes With Insurance Carriers, And Obtaining Commitments Of $3.5 Million In Payments To Company

Hemispherx Biopharma Enters Into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes With Insurance Carriers, And Obtaining Commitments Of $3.5 Million In Payments To Company

CEO Says Series of Coordinated Settlements Should Allow the New Management Team to Focus Exclusively on the Company's Long-Term Commercial, Research and Financial Objectives